ESMO 2017 - Iain McNeish

preview_player
Показать описание
Iain Mcneish discusses the role of PARP inhibitors, including rucaparib in the treatment of ovarian cancer.
  1. Touch Medical Media
Рекомендации по теме
ESMO 2017 - 0:07:37

ESMO 2017 - Iain McNeish

The Ovarian Cancer 0:02:58

The Ovarian Cancer Action Research Centre: How are scientists are working to save lives.

McNeish: Rucaparib for 0:01:40

McNeish: Rucaparib for Treatment of Ovarian Cancer

ARIEL3: Rucaparib as 0:09:31

ARIEL3: Rucaparib as maintenance therapy in recurrent ovarian cancer patients

Immunotherapy & ovarian 0:01:17

Immunotherapy & ovarian cancer

PARP Inhibition’s Role 0:07:34

PARP Inhibition’s Role in Recurrent Ovarian Cancer

Rucaparib May Improve 0:01:21

Rucaparib May Improve PFS in Patients With Ovarian Cancer

Current Landscape of 0:06:54

Current Landscape of PARP Inhibition in Ovarian Cancer

Rucaparib Explored for 0:04:20

Rucaparib Explored for High-Risk Ovarian Cancer

Dr. Coleman on 0:01:14

Dr. Coleman on Benefit of Rucaparib in Ovarian Cancer

Efficacy and Safety 0:06:42

Efficacy and Safety of Rucaparib: A Focus on ARIEL3

Dr. Ledermann on 0:01:20

Dr. Ledermann on Rationale for ARIEL3 Trial in Ovarian Cancer

Rucaparib in Recurrent 0:03:11

Rucaparib in Recurrent Ovarian Cancer: ARIEL3 Trial

PARP Inhibitors in 0:11:05

PARP Inhibitors in Recurrent Ovarian Cancer

Future Directions for 0:21:00

Future Directions for Ovarian Cancer Treatment - Dr Tarek Meniawy

Leading in Crises 0:19:26

Leading in Crises - a chat with Jim McNeish

Ovarian cancer research 0:35:51

Ovarian cancer research update: Learn about 'The Oxford Classic' with Professor Ahmed Ahme...

EASD 2017 - 0:02:40

EASD 2017 - Adela Brahimaj Interview

Shivani Misra om 0:04:10

Shivani Misra om MODY